ProCE Banner Activity

Immunotherapy and Beyond in Metastatic NSCLC: Expert Answers to Your Questions

Clinical Thought

Read our approach to key questions on the management of metastatic NSCLC with chemoimmunotherapy, including our thoughts and views on the evolving treatment landscape and selection between available treatment options based on patient and disease characteristics

Released: January 19, 2024

Share

Faculty

Christine M. Bestvina

Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

Elaine Shum

Elaine Shum, MD

Assistant Professor
NYU Grossman School of Medicine
NYU Perlmutter Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

Christine M. Bestvina, MD: research support: AstraZeneca, Bristol-Myers Squibb; consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CVS, Daiichi Sankyo, Genentech, Jazz, Johnson & Johnson, Novartis, Pfizer, Regeneron, Sanofi, SeaGen, Takeda, Tempus.

Elaine Shum, MD

Assistant Professor
NYU Grossman School of Medicine
NYU Perlmutter Cancer Center
New York, New York

Elaine Shum, MD: consultant/advisor/speaker: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Genentech, Gilead, Regeneron; researcher (paid to institution): Delfi Diagnostics.